SHENZHEN, China, Feb. 8, 2023 /PRNewswire/ -- ImmVira's first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. and China as of January 2023, with which the monotherapy treatment significantly prolonged PFS to a median of 12.9 months among melanoma patients who had failed previous immune-oncology treatment. Currently, late-stage melanoma faces poor prognosis. Clinical studies have found that median PFS of only 1.7 months for stage IV patients, second-line mono immunotherapy achieved median PFS of 2.8 and 3.6 months, combination therapy of PD-1 Ab and VEGF inhibitor achieved median PFS of 4.2 months.

SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay), China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on the Shanghai North Bund as well.

SHENZHEN, China, Aug. 7, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA").

SHENZHEN, China, July 20, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjects with late-stage pancreatic, colon, lung, endometrial, breast, head and neck, gastrointestinal cancers and other advanced tumors. Preliminary biodistribution and clinical results of MVR-T3011 IV demonstrated promising biological activities of MVR-T3011 IV.

SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinical studies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor cobimetinib, to evaluate the safety and efficacy of this combo strategy.

SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing on March 1, 2022 and initiated Phase I clinical trial in a series of well-known domestic clinical study centers in China.